Cerevance has a total of 24 patents globally. Of these 24 patents, more than 66% patents are active. United Kingdom is where Cerevance has filed the maximum number of patents. Parallelly, United Kingdom seems to be the main focused R&D centre and also is the origin country of Cerevance.
Cerevance was founded in 2016. Cerevance is a company that develops innovative treatments with the goal of creating new medications for severe neurological conditions.
Do read about some of the most popular patents of Cerevance which have been covered by us in this article and also you can find Cerevance patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Cerevance patent portfolio.
How many patents does Cerevance have?
Cerevance has a total of 24 patents globally. These patents belong to 14 unique patent families. Out of 24 patents, 16 patents are active.
How Many Patents did Cerevance File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Cerevance Applications Filed | Cerevance Patents Granted |
| 2023 | 6 | – |
| 2022 | 11 | – |
| 2021 | 4 | – |
| 2020 | 2 | – |
| 2019 | 1 | – |
How many Cerevance patents are Alive/Dead?
Worldwide Patents
How Many Patents did Cerevance File in Different Countries?
Countries in which Cerevance Filed Patents
| Country | Patent |
| United Kingdom | 11 |
| Brazil | 1 |
| New Zealand | 1 |
| Mexico | 1 |
| Europe | 1 |
| Canada | 1 |
| Singapore | 1 |
| South Africa | 1 |
| Australia | 1 |
| Israel | 1 |
Where are Research Centers of Cerevance Patents Located?
List of Cerevance patents
| Cerevance Patents | Title |
| EP4211118A1 | Substituted Pyrimidine Derivatives As Nicotinic Acetylcholinesterase Receptor Alpha 6 Modulator |
| WO2023209368A1 | Nitrogen Comprising Heterocyclic Derivatives For The Treatment Of Disorders Associated With Gpr55 Receptor |
| WO2023084206A1 | N-(4-Aminocyclohexyl)Pyrimidine-4-Carboxamide Derivatives As Cd38 Inhibitors |
| AU2022215916A1 | Novel Compounds |
| CA3207461A1 | Novel Compounds |
| IL303838A | Novel Compounds |
| SG11202304919TA | Novel Compounds |
| BR112023015913A2 | New Compounds |
| GB202307427D0 | Novel Compounds |
| GB202307426D0 | Novel Compounds |
| GB2610812A | Novel Compounds |
| GB202216323D0 | Novel Compounds |
| GB202216324D0 | Novel Compounds |
| MX2023009285A | Novel Compounds |
| ZA202308463A | Novel Compounds |
| NZ802792A | Novel Compounds |
| WO2022167819A1 | Novel Compounds |
| WO2022053823A1 | Substituted Pyrimidine Derivatives As Nicotinic Acetylcholinesterase Receptor Alpha 6 Modulator |
| GB202207721D0 | Novel Compounds |
| GB202206054D0 | Novel Compounds |
| GB202101734D0 | Novel Compounds |
| GB202014341D0 | Novel Compounds |
| GB202014342D0 | Novel Compounds |
| GB201907535D0 | Novel Compounds |
What are Cerevance key innovation segments?
What Technologies are Covered by Cerevance?
The chart below distributes patents filed by Cerevance